Cover Image

Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation

This study aimed to investigate the impact of the drug-drug interaction between rivaroxaban and amiodarone on the clinical outcomes in patients with non-valvular atrial fibrillation (NVAF), focusing on pharmacokinetic and pharmacodynamic (PK/PD) aspects. A prospective study enrolling 174 patients wi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Huamin Ding (Author), Zi Wang (Author), Jia Wang (Author), Yao Yao (Author), Chi Zhang (Author), Houwen Lin (Author), Yong Zhou (Author), Zhichun Gu (Author), Qianzhou Lv (Author), Xiaoye Li (Author)
Format:	Book
Published:	MDPI AG, 2024-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita
by: S. N. Bel'diev
Published: (2016)

Clinical Efficacy and Safety Comparison of Rivaroxaban and Dabigatran for Nonvalvular Atrial Fibrillation Patients Undergoing Percutaneous Left Atrial Appendage Closure Operation
by: Xiaoye Li, et al.
Published: (2021)

Perioperative Treatment with Rivaroxaban and Dabigatran on Changes of Coagulation and Platelet Activation Biomarkers following Left Atrial Appendage Closure
by: Yao Yao, et al.
Published: (2024)

Evaluation of Remote Pharmacist-Led Outpatient Service for Geriatric Patients on Rivaroxaban for Nonvalvular Atrial Fibrillation During the COVID-19 Pandemic
by: Xiaoye Li, et al.
Published: (2020)

Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease
by: N. A. Shatalova, et al.
Published: (2023)

Comparative Bleeding Risk of Brand Vs Generic Rivaroxaban in Elderly Inpatients with Atrial Fibrillation
by: Chen G, et al.
Published: (2024)

Rivaroxaban in atrial fibrillation cardioversion: an update
by: Lavalle C, et al.
Published: (2019)

Digoxin and Amiodarone on the Risk of Ischemic Stroke in Atrial Fibrillation: An Observational Study
by: Kuan-Cheng Lai, et al.
Published: (2018)

Cost-Effectiveness of Dronedarone and Amiodarone for the Treatment of Chinese Patients With Atrial Fibrillation
by: Mengran Zhang, et al.
Published: (2021)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016)

Amiodarone prevention for atrial fibrillation relapse after surgical ablation
by: Ivayla Zheleva-Kyuchukova, et al.
Published: (2023)

The Impact of Dabigatran and Rivaroxaban on Variation of Platelet Activation Biomarkers and DRT Following Percutaneous Left Atrial Appendage Closure
by: Xiaoye Li, et al.
Published: (2021)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
by: Turpie AGG
Published: (2014)

Atrial fibrillation in elderly patients. Features of using rivaroxaban
by: A. D. Erlikh
Published: (2020)

Twice-daily rivaroxaban after percutaneous left atrial appendage closure for atrial fibrillation
by: Yang-Qi Pan, et al.
Published: (2024)

ATRIAL FIBRILLATION COMBINED WITH DIABETES MELLITUS. POSSIBILITIES OF USING RIVAROXABAN
by: Alexey D. Ehrlich
Published: (2018)

Effect of Amiodarone, Sotalol and Bisoprolol on Heart Rate Variability in Patients with Atrial Fibrillation
by: E. P. Popova, et al.
Published: (2020)

SAFETY OF AMIODARONE USAGE IN PATIENTS WITH WOLFF-PARKINSON-WHITE SYNDROME AND ATRIAL FIBRILLATION
by: D. A. Kuzhel, et al.
Published: (2016)

Impact of Body Mass Index in the Cardioverter Efficacy of Amiodarone in Persistent Atrial Fibrillation
by: Carmen Ligero, et al.
Published: (2024)

Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation
by: Noppaket Singkham, et al.
Published: (2022)

The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation
by: I. A. Zolotovskaya, et al.
Published: (2021)

Rivaroxaban Precision Dosing Strategy for Real‐World Atrial Fibrillation Patients
by: Robyn Konicki, et al.
Published: (2020)

Influence of ABCB1 Gene Polymorphism on Rivaroxaban Blood Concentration and Hemorrhagic Events in Patients With Atrial Fibrillation
by: Yan Wang, et al.
Published: (2021)

Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban
by: Francisco Marin, et al.
Published: (2023)

New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation
by: article Editorial
Published: (2015)

New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation
by: article Editorial
Published: (2015)

New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation
by: article Editorial
Published: (2015)

Benefits and Harms of Low-Dose Rivaroxaban in Asian Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-World Studies
by: Jun Qian, et al.
Published: (2021)

Comparative efficacy of amiodarone with ivabradin combination or amiodarone with bisoprolol combination in the prevention of atrial fibrillation recurrence in pa- tients with left ventricular diastolic dysfunction
by: K. G. Adamyan, et al.
Published: (2015)

Comparative efficacy of amiodarone with ivabradin combination or amiodarone with bisoprolol combination in the prevention of atrial fibrillation recurrence in pa- tients with left ventricular diastolic dysfunction
by: K. G. Adamyan, et al.
Published: (2015)

Platelet Function and Risk of Bleeding in Patients With Acute Coronary Syndrome Following Tirofiban Infusion
by: Xiaoye Li, et al.
Published: (2019)

Effect of Rivaroxaban in Stroke Prevention in Patient with Atrial Fibrillation due to Valvular Heart Disease
by: Waqar shamim, et al.
Published: (2022)

Time Trends in Patient Characteristics of New Rivaroxaban Users with Atrial Fibrillation in Germany and the Netherlands
by: Annemarie Voss, et al.
Published: (2023)

CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: S. V. Nedogoda, et al.
Published: (2017)

Prophylactic effect of Amiodarone and in combination with vitamin C in reducing atrial fibrillation after coronary artery bypass
by: Alireza Kamali, et al.
Published: (2021)

Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study
by: Michael Becka, et al.
Published: (2012)

Comparison of Efficacy and Safety Between Dronedarone and Amiodarone Used During the Blind Period in Patients with Atrial Fibrillation After Catheter Ablation
by: Li Y, et al.
Published: (2023)

Does Rivaroxaban Better than Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing PCI?
by: Maamar Kara, et al.
Published: (2016)